B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites

Cui,Shuzhong; Ba,Mingchen; Tang,Yunqiang; Liu,Jifang; Wu,Yinbing; Wang,Bin; Zhang,Xiangliang; Tang,Hongsheng; Zhong,Shizhen

doi:10.3892/or.2012.1913

B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites

Authors:
- Shuzhong Cui
- Mingchen Ba
- Yunqiang Tang
- Jifang Liu
- Yinbing Wu
- Bin Wang
- Xiangliang Zhang
- Hongsheng Tang
- Shizhen Zhong
View Affiliations

Affiliations: The Institute of Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, P.R. China, Intracelom Hyperthermic Perfusion Therapy Center, Cancer Hospital of Guangzhou Medical College, Guangzhou 510095, P.R. China
Published online on: July 13, 2012 https://doi.org/10.3892/or.2012.1913
Pages: 1325-1331

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To minimize invasive surgery, we employed B ultrasound to guide the placement of the catheters used in continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy (CHIPC) in malignant ascites treatment. Thirty-two patients with malignant ascites were treated with CHIPC guided by B-mode ultrasound. Ascites were originally from ovarian cancer (11 cases), gastric cancer (10 cases), colorectal cancer (9 cases) and pancreatic cancer (2 cases). The CHIPC was carried out at 43˚C for 90 min with 0.9% saline solution as a carrier containing cisplatin and doxorubicin or mitomycin-C as therapeutic reagents depending on the type of the primary tumor. The therapeutic efficacy, postoperative complications and survival period of these patients were assessed with follow-up examinations. Among all participates to be assessed with ascites, 26 and 4 patients showed complete remission (CR) and partial remission (PR) respectively, with an objective remission rate (ORR) of 93.75%. The KPS scores were elevated by 23.1±9.0 after 3 sessions of ultrasound guided CHIPC and the quality of life (QOF) of patients was significantly improved (p<0.01). The median survival time was 9 months and 18 patients survived between 3 and 30 months after CHIPC treatment. Additionally, patients with different types of cancers significantly differed in the survival time (p<0.01). A novel approach of using B ultrasound guided CHIPC for the treatment of malignant ascites demonstrated satisfactory outcomes. The approach shows benefit in minimizing invasive surgery, improving the patient QOF and prolonging survival time.

View Figures

View References

1	Patriti A, Cavazzoni E, Graziosi L, et al: Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech. 18:426–428. 2008. View Article : Google Scholar
2	Becker G, Galandi D and Blum HE: Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 42:589–597. 2006. View Article : Google Scholar : PubMed/NCBI
3	Woopen H and Sehouli J: Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res. 29:3353–3359. 2009.PubMed/NCBI
4	Aarts F, Hendriks T, Boerman OC, Koppe MJ, Oyen WJ and Bleichrodt RP: A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats. Ann Surg Oncol. 14:3274–3282. 2007. View Article : Google Scholar
5	Kusamura S, Younan R, Baratti D, et al: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 106:1144–1153. 2006. View Article : Google Scholar
6	Levine EA, Stewart JH IV, Russell GB, Geisinger KR, Loggie BL and Shen P: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 204:943–953. 2007. View Article : Google Scholar
7	Spratt JS, Adcock RA, Muskovin M, Sherrill W and McKeown J: Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 40:256–260. 1980.PubMed/NCBI
8	Zanon C, Bortolini M, Chiappino I, et al: Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer. World J Surg. 30:2025–2032. 2006. View Article : Google Scholar : PubMed/NCBI
9	Al-Shammaa HA, Li Y and Yonemura Y: Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol. 14:1159–1166. 2008. View Article : Google Scholar
10	Benoit L, Cheynel N, Ortega-Deballon P, Giacomo GD, Chauffert B and Rat P: Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surg Oncol. 15:542–546. 2008. View Article : Google Scholar
11	Huh JW, Kim YJ and Kim HR: Complete peritonectomy and intraperitoneal chemotherapy for recurrent rectal cancer with peritoneal metastasis. World J Gastroenterol. 15:756–757. 2009. View Article : Google Scholar : PubMed/NCBI
12	Spratt JS, Adcock RA, Sherrill W and Travathen S: Hyperthermic peritoneal perfusion system in canines. Cancer Res. 40:253–255. 1980.PubMed/NCBI
13	Ba MC, Cui SZ, Lin SQ, et al: Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol. 16:1901–1907. 2010. View Article : Google Scholar
14	Facchiano E, Scaringi S, Kianmanesh R, et al: Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol. 34:154–158. 2008. View Article : Google Scholar
15	Ferron G, Gesson-Paute A, Classe JM and Querleu D: Feasibility of laparoscopic peritonectomy followed by intra-peritoneal chemohyperthermia: an experimental study. Gynecol Oncol. 99:358–361. 2005. View Article : Google Scholar : PubMed/NCBI
16	Garofalo A, Valle M, Garcia J and Sugarbaker PH: Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol. 32:682–685. 2006. View Article : Google Scholar
17	Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E and Querleu D: Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. Ann Surg Oncol. 15:339–344. 2008. View Article : Google Scholar
18	Di Giorgio A, Naticchioni E, Biacchi D, et al: Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 113:315–325. 2008.
19	Elias D, Lefevre JH, Chevalier J, et al: Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 27:681–685. 2009. View Article : Google Scholar : PubMed/NCBI
20	Fujimoto S, Shrestha RD, Kokubun M, et al: Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg. 208:36–41. 1988. View Article : Google Scholar
21	Helm CW, Bristow RE, Kusamura S, Baratti D and Deraco M: Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol. 98:283–290. 2008. View Article : Google Scholar : PubMed/NCBI
22	Scaringi S, Kianmanesh R, Sabate JM, et al: Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience. Eur J Surg Oncol. 34:1246–1252. 2008. View Article : Google Scholar
23	Shido A, Ohmura S, Yamamoto K, Kobayashi T, Fujimura T and Yonemura Y: Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion? World J Surg. 24:507–511. 2000. View Article : Google Scholar : PubMed/NCBI
24	Inadomi J, Cello JP and Koch J: Ultrasonographic determination of ascitic volume. Hepatology. 24:549–551. 1996.
25	Ozkan O, Akinci D, Gocmen R, Cil B, Ozmen M and Akhan O: Percutaneous placement of peritoneal port-catheter in patients with malignant ascites. Cardiovasc Intervent Radiol. 30:232–236. 2007. View Article : Google Scholar : PubMed/NCBI
26	Kaushik N, Khalid A, Brody D and McGrath K: EUS-guided paracentesis for the diagnosis of malignant ascites. Gastrointest Endosc. 64:908–913. 2006. View Article : Google Scholar : PubMed/NCBI
27	Nguyen PT and Chang KJ: EUS in the detection of ascites and EUS-guided paracentesis. Gastrointest Endosc. 54:336–339. 2001. View Article : Google Scholar : PubMed/NCBI
28	Knutsen A, Sielaff TD, Greeno E and Tuttle TM: Staged laparoscopic infusion of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery. J Gastrointest Surg. 10:1038–1043. 2006. View Article : Google Scholar